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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comrevascularization and cerebral vascular accidents) 1 year after DES implantation in
the Pio-treated group was signiﬁcantly decreased (6.6%) compared with that with
other therapies in the group without Pio (12.0%, P< 0.01). The rate of CV events
3 years after DES implantation in the Pio-treated group was signiﬁcantly decreased
(10.6%) compared with that with other therapies in the group without Pio (19.1%,
P< 0.01).
Conclusions: Pioglitazone signiﬁcantly decreases CV events of Japanese patients
with DM after DES implantation according to 1-year and 3-year follow-up results.
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Background: Aim of the present study is to investigate 1-year clinical outcomes after
implantation of BVS vs. EES in all-comer diabetic patients, including those with
complex lesion characteristics.
Methods: Consecutive diabetic patients treated with BVS between May 2007 and
April 2014 and those treated with EES between December 2006 and August 2012 in
two Italian centers were included in this retrospective study. One-year clinical out-
comes of major adverse cardiac event (MACE: composite of all-cause mortality, any
myocardial infarction and target vessel revascularization) and target lesion revascu-
larization (TLR) were compared between the two groups.
Results: Forty eligible patients (65 lesions) treated with BVS, and 264 (356 lesions)
treated with EES were enrolled. Mean age (BVS: 62.81.9 vs. EES: 65.71.6,
p¼0.13) and male gender (92.5% vs. 82.2%, p¼0.11) were similar in both groups.
The use of insulin (32.5% vs. 30.7%), prevalence of chronic kidney disease (22.5% vs.
21.5%, p¼1.00) and ejection fraction (55.0 (IQR: 50.0-60.0) vs. 55.0 (50.0-60.0),
p¼0.48) were also similar. With regards to lesion characteristics, total stent length per
patient was higher in the BVS compared to the EES group (28mm (28-55) vs 23mm
(18-36), p< 0.001). At 1-year follow-up, MACE occurred in 17.9% patients in the
BVS group and 14.2% in the EES group (p¼0.36), whereas TLR occurred in 8.9% of
patients in the BVS and 7.2% in the EES group (p¼0.76). After 1:2 propensity
matching (40 BVS patients:80 EES patients), 1-year MACE was observed in 17.9% of
BVS patients vs 8.9% of EES (p¼0.077). TLR was 8.9% in the BVS group and 3.9%
in the EES group (p¼0.19). The major contribution to MACE were periprocedural
myocardial infarctions (pMI: CK-MB>5) (7.5% with BVS and 0% with EES). A
more aggressive predilatation and postdilation and the thicker stent struts of BVS may
explain the higher incidence of pMI.
Conclusions: BVS implantation in all comer diabetics, including those with complex
coronary lesions is feasible with acceptable 1-year outcomes when compared to EES.
The higher incidence of pMI warrants further investigation.
TCT-245
Diabetic patients treated with Bioresorbable Vascular Scaffolds show good
clinical outcomes at two-year follow-up: A pooled analysis from the ABSORB
and SPIRIT trials
Javaid Iqbal1, Yoshinobu Onuma2, Robert J. Van Geuns2, Bernard Chevalier3,
Takashi Muramatsu2, Yao-Jun Zhang2, Susan Veldhof4, Pieter C. Smits5,
Robert J. Whitbourn6, Antonio L. Bartorelli7, Gregg W. Stone8, Alexandre Abizaid9,
Patrick W. Serruys2
1Thorax center, Erasmus MC, Rotterdam, Netherlands, 2Thorax Center, Erasmus MC,
Rotterdam, Netherlands, 3ICPS, Massy, France, 4Abott Vascular International BVBA,
Diegem, Belgium, 5Maasstad Hospital Rotterdam, Rotterdam, Netherlands,
6Cardiovascular Research Centre, St. Vincent Hospital Melbourne, Melbourne,
Australia, 7University of Milan, Milan, Italy, 8Columbia University Medical Center
and the Cardiovascular Research Foundation, New York, United States, 9Instituto
Dante Pazzanese de Cardiologia, São Paulo, Brazil
Background: Diabetes mellitus is a risk factor for poor outcomes after PCI. The
newer-generation metallic drug-eluting stents (DES) have improved outcomes in non-
diabetics, but outcomes remain poor in diabetics. Bioresorbable scaffolds are novel
devices for coronary revascularization; however, long-term clinical outcomes of these
devices in diabetics have not been reported. Aim of this study was to evaluate 2-year
clinical outcomes in diabetic patients treated with everolimus-eluting bioresorbable
vascular scaffolds (BVS).
Methods:We compared outcomes in 142 diabetics and 434 non-diabetics treated with
BVS from Absorb Cohort B and Absorb EXTEND. Furthermore, BVS treated di-
abetics (n¼103) were compared with propensity matched diabetics (n¼175) treated
with metallic XIENCE everolimus-eluting stents (EES) from SPIRIT First, II, III and
IV studies. Patient-oriented composite endpoint (PoCE, including all death, all MI,
and all revascularizations), device-oriented composite endpoint (DoCE, including
cardiac death, target vessel MI, or target lesion revascularization) and scaffold/
stent thrombosis (deﬁnite and probable according to ARC) were assessed at 2-year
follow-up.B72 JACC VolResults: BVS treated diabetics had similar baseline characteristics as BVS treated
non-diabetics except for the presence of diabetes and hypertension. At 2-year follow-
up, there were no signiﬁcant differences in PoCE (diabetics 10.6% vs non-diabetics
12.9%, p¼0.46), DoCE (diabetics 4.2% vs non-diabetics 7.6%, p¼0.16) and scaffold
thrombosis (diabetics 0.7% vs non-diabetics 0.9%, p¼1.0) between the two groups.
BVS and EES treated diabetics were well-matched for demographic, clinical and
procedural characteristics, except for longer duration of DAPT in the BVS group.
PoCE (BVS 12.6% vs EES 10.9%, p¼0.66), DoCE (BVS 5.8% vs EES 5.7%,
p¼0.97) and scaffold/stent thrombosis (BVS 1.0% vs EES 0.6%, p¼1.0) were similar
in the diabetics treated with BVS or EES at 2-year follow-up.
Conclusions: Patient- and device-oriented outcomes in BVS treated patients were
independent of diabetic status, and were comparable to the outcomes observed with
EES. A prospective randomized clinical trial is warranted to determine the optimal
device for diabetic patients.
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Background: Diabetes is associated with diffuse coronary artery disease and worse
clinical outcome after stenting with metallic stents. Everolimus-eluting bioresorbable
vascular scaffolds (BVS, Abbott Vascular, Santa Clara, California, USA) represent a
new approach. This study aimed to evaluate feasibility and mid-term clinical outcome
after implantation of BVS in diabetics.
Methods: All patients with diabetes who had been treated with BVS in the vicinity of
our all-comers registry were included, irrespective of their clinical presentation. Target
parameters were target vessel failure (TVF), major adverse cardiac events (MACE)
including target lesion revascularization (TLR), cardiac death, myocardial infarction
and emergency coronary bypass graft surgery. Follow-up was performed by telephone
call and/ or ofﬁce visit.
Results: A total of 100 patients were included, of whom 15 % had a STEMI, 20 % a
NSTEMI, 13 % presented instable angina and 52 % stable angina. Median age was 67
(60-73) years, 29%were female, 97% suffered from hypertension. Of all patients, 36%
patients have an insulin-dependent diabetes, all other patients were treated with oral
antidiabetics or dietary. Median procedure time was 56.5 min (41 – 70), mean contrast
volume was 178.3 mL ( 92.3). A total of 105 bioresorbable vascular scaffolds were
implanted with a mean number of 1.4  0.8 per patient. There was no implantation
possible in two cases. Median follow-up duration was 175 (59 – 316) days. Three
scaffold thromboses occurred, of which two were most probably due to discontinuation
of dual antiplatelet therapy. One in-scaffold restenosis was noted. In summary the total
rates of TVF, TLR and MACE were 5.1, 4.1 and 8.0 %, respectively.
Conclusions: Since the experience with bioresorbable vascular scaffolds in speciﬁc
subsets is limited, this study conﬁrms safety of bioresorbable vascular scaffold im-
plantation in diabetics. Furthermore our results demonstrate satisfying mid-term
clinical outcome. DAPT seems to be extraordinary crucial to prevent scaffold
thrombosis. Nevertheless, long-term data is required for ﬁnal evaluation.
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Background: Percutaneous coronary intervention (PCI) of small vessels has been
associated with high risk of recurrent events, especially in patients with diabetes
mellitus (DM).
Methods: We examined outcomes of patients with small reference diameter (2.5
mm) vessels who underwent PCI using ResoluteTM zotarolimus-eluting stent (R-
ZES) in the pooled RESOLUTE program stratiﬁed by diabetic status. Target Lesion
Failure (TLF) was composite of death from cardiac causes, target vessel myocardial
infarction (TV-MI), and target lesion revascularization (TLR). The incidence of
clinical events was calculated using the Kaplan Meier method.
Results: Among 2721 patients with at least one small vessel lesion treated with R-
ZES, 233 patients had insulin dependent DM (IDDM), 724 patients had non-insulin
dependent diabetes mellitus (non-IDDM), and 1764 patients did not have diabetes (no-
DM). There were signiﬁcant differences in baseline characteristics, in particular
greater complexity with IDDM patients. At 3-years, TLR was similar in non-DM and
NIDDM, and was signiﬁcantly lower than in IDDM patients (Figure). Similarly, TLF
(9.7% vs. 11.1% vs. 21.8%, p< 0.001), CD/TV-MI (5.6% vs. 7.4% vs 11.8%,
p¼0.002), and ARC Deﬁnite/Probable ST (0.9% vs. 1.1% vs. 1.3%, p¼0.81), were
lower among non-DM and NIDDM patients.
Conclusions: Among patients undergoing PCI with small vessels in the pooled
RESOLUTE program, NIDDM and non-DM patients had similar 3-year outcomes,
which was lower than with IDDM. These outcomes demonstrate the long-term safety
and effectiveness of R-ZES in complex NIDDM and non-DM patients. Submitted on
behalf of the RESOLUTE Global Clinical Program64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Diabetes
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Background: There is currently no data to evaluate the differences of drug-eluting
stents on the angiographic outcomes of diabetes mellitus (DM) patients. To evaluate
the effects of different drug-eluting stents on the outcomes of DM patients, we
investigated serial angiographic outcomes after drug-eluting stent placement.
Methods: From 2002 to 2012, 10983 consecutive de-novo coronary lesions were
treated using drug-eluting stents (biolimus-eluting stent (BES); n¼1367, everolimus-
eluting stent (EES); n¼2983, paclitaxel-eluting stent (PES); n¼1215, sirolimus-
eluting stent (SES); n¼5418). 41% were DM and 10% were insulin-treated patients.
Angiographic follow-up was routinely performed 8 months after a successful proce-
dure (follow-up rate was 82%). Angiographic outcomes were compared among pa-
tients with the implanted stent types.
Results: The binary restenosis rates were 6.6% in non-DM patients, 11.0% in non-
insulin-requiring DM patients, and 14.0% in insulin-treated DM patients. The SES,
PES and BES groups had higher restenosis rates in non-insulin-requiring DM patients
compared with non-DM patients (SES; 6.1% vs. 10.4%, p< 0.001, PES; 12.0% vs.
21.7%, p< 0.001, BES 5.9% vs. 9.1%, p¼0.04). Binary restenosis in the EES group
were similar between non-DM patients and non-insulin-requiring DM patients (5.5%
vs. 5.6%, p¼0.92). A multivariable analysis showed that DM was an independent
predictor of recurrent restenosis in implantation of SES (odds ratio [OR]: 1.98, 95%
conﬁdence interval [CI]: 1.59 to 2.46, p< 0.001), PES (OR: 1.74, CI: 1.22 to 2.48,
p¼0.002), and BES (OR: 1.60, CI: 1.01 to 2.53, p¼0.04), except EES (OR: 1.19, CI:
0.85 to 1.67, p¼0.30).
Conclusions: Percutaneous coronary intervention in DM patients is associated with
worse angiographic outcomes compared with those in non-DM patients. The use of
EES could be effective for DM patients.
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Background: To evaluate whether the impact on clinical outcomes of newer vs. ﬁrst
generation drug-eluting stents (DES) is inﬂuenced by diabetes mellitus (DM).
Methods: We pooled patient-level data of 10,448 women undergoing PCI with DES
from 26 randomized trials. Baseline characteristics and long-term clinical outcomes
were stratiﬁed according to baseline DM status and DES type (new vs. ﬁrst genera-
tion). Associations between stent type and outcomes were examined within each
stratum using Cox regression with trial entered as a random effect. The primary
endpoint was the composite of all-cause death and myocardial infarction (MI). Sec-
ondary endpoints were target-lesion revascularization (TLR) and deﬁnite or probable
stent thrombosis (ST).
Results: DM was present in 3,294 (31.5%) of women treated with DES. In women
without DM, use of new generation compared with ﬁrst generation DES was asso-
ciated with reduced risks of death or MI (7.6% vs. 10.2%; adjHR 0.69, 95%CI, 95%CI
0.55-0.88), ST (0.8% vs. 1.7%; adjHR 0.32, 95%CI 0.17-0.62) and TLR (5.3% vs.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Li6.9%; adjHR 0.74, 95%CI 0.56-0.99). No major differences were observed between
new and ﬁrst generation DES for death or MI (12.8% vs. 12.4%; adjHR 0.90, 95%CI,
95%CI 0.69-1.19), ST (2.0% vs. 3.1%; adjHR 0.84, 95%CI 0.47-1.49) and TLR
(8.7% vs. 9.5%; adjHR 1.14, 95%CI 0.82-1.59) among women with DM (Figure).
Interaction testing was signiﬁcant for the outcome of def/prob ST (p¼0.04).
Supporting File(s)
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Conclusions: The safety and efﬁcacy proﬁle of new generation compared with ﬁrst
generation DES among women varies according to the presence of DM with enhanced
beneﬁts in women without DM.
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Background: It is still unknown whether different stent types of new-generation
cobalt-chromium drug-eluting stent (DES) correlate with clinical outcomes in patients
with diabetes.
Methods: Across 2 Italian centers, we retrospectively evaluated the primary endpoint
of major adverse cardiac events (MACE) amongst patients receiving new-generation
zotarolimus-eluting stents (ZES: Resolute family [Medtronic, Santa Rosa, CA]) and
everolimus-eluting stents (EES: Xience family [Abbott Vascular, Santa Clara, CA]
and PROMUS stent [Boston Scientiﬁc, Natick, MA]). Secondary endpoints included
the composite endpoint of all-cause mortality and any myocardial infarction (MI), and
any target lesion revascularization (TLR).
Results: Four hundred patients with 553 coronary lesions treated with ZES (136
patients, 196 lesions) and EES (264 patients, 357 lesions) between October 2006 and
August 2012 were included in the present study. Patient demographics and other
cardiovascular risk factors were similar between the two groups. Multi-vessel PCI
(23.5% vs. 14.0%, p¼0.017), a PCI for restenotic lesion (26.0% vs. 15.4%, p¼0.002),
IVUS usage (30.1% vs. 17.4%, p¼0.001) were signiﬁcantly higher in the ZES group,
whereas implantation of smaller vessel stents (2.5mm) was statistically higher in the
EES group (27.6% vs. 37.8%, p¼0.015). At the follow-up period of 720 days, there
was no signiﬁcant difference in MACE between ZES and EES (22.8% vs. 18.1%,
HR¼1.11, 95%CI: 0.67-1.85). Similarly no signiﬁcant differences were observed in
the composite endpoint of death or MI (9.1% vs. 10.3%, HR¼1.14, 95%CI: 0.54-
2.40) or TLR (12.4% vs. 6.9%, HR¼1.53, 95%CI; 0.81-2.89).
Conclusions: The present study showed that no signiﬁcant differences in each outcomes
(MACE, all-cause mortality/MI, TLR) were observed in diabetic patients treated with
new-generation cobalt-chromium ZES and EES. Even though, our study cohort
constituted of more complex lesions and patient characteristics, our ﬁndings resemble
the ones reported in previous randomized control studies in the general population.Lipid Disorders and Management
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Background: Reducing the expression of endothelial cell adhesion molecules
(ECAMs) is conducive to the decrease of inﬂammation-induced vascular complica-
tions. In this study, we observed Pitavastatin on the expression of vascular cell
adhesion molecule-1 (VCAM-1) and its inﬂuence on VCAM-1’s target gene miR-126
in cultured human umbilical vein endothelial cells (HUVEC) activated by tumor
ncrosis factor-a (TNF-a). The purpose of this study is to explore the mechanism of
pitavastatin in prevention and treatment of atherosclerosis (AS).
Methods: HUVEC were cultured in M1640 supplemented with 10% bovine calf serum
and passages 2 to 5were used in experiments. The cells were randomly divided into threepid Disorders and Management B73
